Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,256 across all filing types
Latest filing 2025-11-10 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed intimation of the Company as per the captioned subjecy for your reference.
Regulatory Filings
2025-11-10 English
General Updates
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the resignation of a company secretary, Ms. Manasa R. It references compliance with SEBI regulations (Listing Obligations and Disclosure Requirements) and includes details about the resignation and cessation date. There is no financial data, report, or presentation included. The content clearly pertains to a change in senior management personnel. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming the classification.
2025-11-10 English
Disclosure of material issue
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the resignation of a company secretary, Ms. Manasa R, from AstraZeneca Pharma India Limited. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events or information. The content focuses on management change, specifically the resignation of a senior management official, and includes annexures with resignation details. There is no financial data, earnings information, or report publication mentioned. The document is not an annual or interim report, audit report, or earnings release. It clearly fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-11-10 English
Disclosure of material issue
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the resignation of a Company Secretary, Ms. Manasa R, from AstraZeneca Pharma India Limited. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of events or information. The content focuses on management change, providing details about the resignation and handover period. There is no financial data, audit information, or report publication mentioned. The document is clearly an announcement of a change in senior management personnel, fitting the category of Board/Management Information (MANG). The document length is short and does not contain any financial statements or detailed reports, so it is not an Annual Report or Interim Report. Therefore, the appropriate classification is MANG with high confidence.
2025-11-10 English
Disclosure of material issue
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the resignation of a company secretary, Ms. Manasa R, from AstraZeneca Pharma India Limited. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events or information. The content focuses on management change, including resignation details and handover period, without any financial data or report attachments. The document length is short (2104 characters), and it is clearly an announcement of a management change rather than a full report or financial filing. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-11-10 English
Please find the enclosed document of the Company as per the captioned subject for your reference.
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the resignation of a company secretary, Ms. Manasa R, from AstraZeneca Pharma India Limited. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events or information. The content includes details about the resignation, effective date, and a resignation letter annexure. There is no financial data, earnings information, or report publication mentioned. This fits the category of Board/Management Information (MANG), as it announces a change in senior management.
2025-11-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.